News & Insights
Keep up to date on current investment news.
Investing in Medical Technology
Understanding Medical Technology:
Exploring New Frontiers with Maybank Strategic Growth-I Fund
Medical Technology: Pulsed Field Ablation
Sources: CDC
Atrial fibrillation (“AFib”): A Silent Killer
of global deaths are caused by cardiovascular disease.
of these deaths were due to heart attack and stroke, and AFib increases the risk of stroke.
What is AFib?
AFib is an irregular heart rhythm that may lead to compilation like heart failure.
Sources: JNJ Medtech
Sources: JNJ Medtech
In 2021,
43 million
people suffered Afib globally
It is expected to reach
72 million
Afib patients by 2050, placing huge burden across the globe
Pulsed Field Ablation (“PFA”): Revolutionizing AFib Treatment
- PFA is a technique used to treat arrhythmias like AFib by delivering electrical pulses to disrupt abnormal heart tissue.
- Medical technology companies are enhancing AFib treatment by replacing traditional methods with PFA.
- PFA reduces the risk and delivers high efficacy, shorter procedure times, and superior safety profile with lower complication rate.
| Feature | Pulsed Field Ablation (PFA) | Cryoballoon Ablation (CRYO) | Radiofrequency Ablation (RF) |
|---|---|---|---|
| First-Pass Isolation Rate | 98.8% | 98.8% | 73.1% |
| Procedure Time | Shorter (average 94 minutes) | Longer (average 76 minutes) | Longer (average 157 minutes) |
| Complication Rates | ~3.4% | ~8.6% | ~5.5% |
| Phrenic Nerve Palsy Risk | None Reported | Risk present | Risk present |
| Long-Term Freedom from AFib | 79.3% at 1 year | 74.7% at 1 year | 72.4% at 1 year |
Source: National Library of Medicine, Cardiovascular Research Foundation, Journal of the American College of Cardiology
Note: While this fund invests in digitisation of cash, it also includes other sectors in its portfolio. Please consider this when evaluating your investment decisions.
Disclaimer: This material contains a brief description of the fund and is not exhaustive. Investors are advised to request, read and understand the Prospectus before deciding to invest. The Prospectus for Maybank Global Strategic Growth-I Fund dated 10 July 2024 and its supplementaries if any (“Prospectus”) have been lodged with the Securities Commission Malaysia (“SC”), who takes no responsibility for its contents. A copy of the Prospectus can be obtained at our office or at our distributor’s branches. Investors are again advised to read and understand the content of the Prospectus before investing. Among others, Investors should consider the fees and charges involved. The price of units and distribution made payable, if any, may go down as well as up. The past performance of the fund should not be taken as indicative of its future performance.
The Securities Commission Malaysia takes no responsibility for the content of this material and expressly disclaims all liability arising from this material.
Related News
